Pharmaceutical - Basilea Pharmaceutica


Current filters:

Basilea Pharmaceutica

Popular Filters

Astellas amends license deal for isavuconazole with Basilea


Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Report looks at impact of new law governing clinical trials in Switzerland

Report looks at impact of new law governing clinical trials in Switzerland


Clinical trials in Switzerland have been the subject of a new report carried out by the Swiss Federal…

Basilea PharmaceuticaEli LillyEuropeLegalNovartisPharmaceuticalResearchRoche

Astellas’ antifungal study reports positive results


Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development


Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

GlaxoSmithKline gets global rights to Basilea's Toctino


UK pharma giant GlaxoSmithKline (LSE: GSK) says that its dermatology-focussed subsidiary Stiefel has…

Basilea PharmaceuticaceftobiproleDermatologicalsGlaxoSmithKlineisavuconazoleLicensingPharmaceuticalResearchStiefelToctino

Licensing deal for Basilea in sight


The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea’s…

Antibiotics and Infectious diseasesBasilea PharmaceuticaceftobiproleDermatologicalsLicensingPharmaceuticalResearchToctino

Back to top